Moderna, Inc. (MRNA) shares climbed 9.9% to $154.27 as of September 2, 2026, a significant gain from the prior close of $140.34. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
MRNA climbed 9.9% to $154.27
MRNA climbed 9.9% in its latest session, moving from $140.34 to $154.27.
ValuationMedium confidence
Rel. volume
2.0×
Very High
Vs peers
—
No comparable peers
Market cap
$61.2B
NASDAQ Global Select
Analyst target
$115
-25.6% vs price
Price chart
Sep 2
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 9.9% price move with conviction. Weighing against that: Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga); MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06. Wall Street's consensus price target sits at $114.82, implying -25.6% downside from $154.27. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality medium (67/100). With earnings roughly 64 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $154.27, up $13.93 (+9.93%) from the previous close of $140.34. The session traded on 2.0× average volume (very high), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $114.82, 25.6% below the recent $154.27. Over the past 90 days analysts logged 2 upgrades, 12 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRNA line up.
▲ The bullish case
+The Street's most bullish target is $245.00 (+58.8%).
+2 analyst upgrades in the past 90 days, most recently Wolfe Research to Peer Perform (2026-08-25).
+Material positive event.
+Strong 9.9% price move with conviction.
+Volume 2.0x average — institutional conviction.
▼ The bearish case
−The consensus analyst price target of $114.82 sits 25.6% below the recent $154.27, so the average target sees limited room to run.
−The most bearish analyst target is $25.00 (-83.8%).
−Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga).
−MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06.
−Moderna, Inc. (MRNA) moved -7.51% from $68.28 to $63.15 on 2026-07-16.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 2, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Analyst expectations
Consensus target: $115-25.6%
↑ 2 upgrades= 12 maintains
Wolfe Research upgraded to Peer Perform · 2026-08-25
Moderna, Inc. (MRNA) moved +4.65% from $134.10 to $140.34 on 2026-08-31. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on below-average volume (0.6x the 5-day average).
Moderna shares fell 6.90% to $147.87 intraday, with volume at 1.24x the time-adjusted expected level. The evidence identifies this move as a tracked event on 2026-08-26 cited by Morningstar and Yahoo Finance, though the specific driver is not disclosed in the available sources. The decline occurs ahead of the company's November earnings report (consensus EPS estimate: -$1.38).
Moderna surged +10.98% to $154.14 on fresh analyst upgrades and continued momentum from its cancer vaccine breakthrough. Wolfe Research upgraded the stock this morning, building on Bank of America's $170 price-target raise last week and the company's landmark Phase 3 trial success for its personalized mRNA melanoma vaccine (developed with Merck), per Benzinga and Yahoo Finance.
Moderna rallied 7.18% to $142.89 as traders repositioned following a historic 177% surge earlier in the week sparked by positive late-stage melanoma vaccine trial results with Merck (reported by 247wallst.com and Yahoo Finance). The stock is experiencing volatile whipsaw trading with volume at 5.27x the time-adjusted average, driven by short-term traders and algorithmic funds resetting positions after Wednesday's breakout and Thursday's pullback; no fresh clinical or corporate data emerged on Friday.
Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga). The collapse follows a prior rally that had pushed MRNA up 177% and triggered a spillover rally in semiconductor stocks; volume is elevated at 7× normal levels for this time of session, signaling heavy institutional and retail liquidation.
Material / Earnings2026-08-19
Moderna, Inc. (MRNA) moved +50.30% from $116.02 to $174.38 on 2026-08-19 on continued investor optimism around Phase 3 clinical milestone data for its personalized mRNA cancer vaccines (developed with Merck) and progress across its non-COVID infectious disease and latent virus programs. Volume surged to 34.0x the 5-day average.
Material / Earnings2026-08-12
Moderna, Inc. (MRNA) moved +5.11% from $60.58 to $63.67 on 2026-08-12. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move was not driven by unusual trading activity.
Activity2026-08-07
Moderna, Inc. (MRNA) moved +7.99% from $54.79 to $59.17 on 2026-08-07. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average.
In-depth MRNA event analyses
Permanent, dated analyses of MRNA's most significant sessions.
MRNA climbed 9.9% to $154.27. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock rise?
MRNA gained 9.93% ($13.93) versus the prior close of $140.34, last trading at $154.27 on 2.0× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-05 — about 64 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $114.82, about 25.6% below the current $154.27. Over the past 90 days, analysts recorded 2 upgrades, 12 maintains, and 0 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
